178 related articles for article (PubMed ID: 24942536)
1. Polymeric Plerixafor: effect of PEGylation on CXCR4 antagonism, cancer cell invasion, and DNA transfection.
Wang Y; Li J; Oupický D
Pharm Res; 2014 Dec; 31(12):3538-48. PubMed ID: 24942536
[TBL] [Abstract][Full Text] [Related]
2. Balancing polymer hydrophobicity for ligand presentation and siRNA delivery in dual function CXCR4 inhibiting polyplexes.
Wang Y; Li J; Chen Y; Oupický D
Biomater Sci; 2015 Jul; 3(7):1114-23. PubMed ID: 26146552
[TBL] [Abstract][Full Text] [Related]
3. Effect of biodegradability on CXCR4 antagonism, transfection efficacy and antimetastatic activity of polymeric Plerixafor.
Li J; Oupický D
Biomaterials; 2014 Jul; 35(21):5572-9. PubMed ID: 24726746
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and application of poly(ethylene glycol)-co-poly(β-amino ester) copolymers for small cell lung cancer gene therapy.
Kim J; Kang Y; Tzeng SY; Green JJ
Acta Biomater; 2016 Sep; 41():293-301. PubMed ID: 27262740
[TBL] [Abstract][Full Text] [Related]
5. AMD3100 conjugates as components of targeted nonviral gene delivery systems: synthesis and in vitro transfection efficiency of CXCR4-expressing cells.
Le Bon B; Van Craynest N; Daoudi JM; Di Giorgio C; Domb AJ; Vierling P
Bioconjug Chem; 2004; 15(2):413-23. PubMed ID: 15025540
[TBL] [Abstract][Full Text] [Related]
6. The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signaling.
Berning P; Schaefer C; Clemens D; Korsching E; Dirksen U; Potratz J
Cell Commun Signal; 2018 May; 16(1):21. PubMed ID: 29776413
[TBL] [Abstract][Full Text] [Related]
7. Treatment of acute lung injury and early- and late-stage pulmonary fibrosis with combination emulsion siRNA polyplexes.
Wang Y; Ding L; Li Z; Chen G; Sun M; Oupicky D
J Control Release; 2019 Nov; 314():12-24. PubMed ID: 31644934
[TBL] [Abstract][Full Text] [Related]
8. CXCR4 antagonist inhibits perineural invasion of adenoid cystic carcinoma.
Jeong WJ; Choi IJ; Park MW; An SY; Jeon EH; Paik JH; Sung MW; Ahn SH
J Clin Pathol; 2014 Nov; 67(11):992-8. PubMed ID: 25118295
[TBL] [Abstract][Full Text] [Related]
9. A Lentiviral CXCR4 overexpression and knockdown model in colorectal cancer cell lines reveals plerixafor-dependent suppression of SDF-1α-induced migration and invasion.
Heckmann D; Laufs S; Maier P; Zucknick M; Giordano FA; Veldwijk MR; Eckstein V; Wenz F; Zeller WJ; Fruehauf S; Allgayer H
Onkologie; 2011; 34(10):502-8. PubMed ID: 21985848
[TBL] [Abstract][Full Text] [Related]
10. CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models.
Gravina GL; Mancini A; Muzi P; Ventura L; Biordi L; Ricevuto E; Pompili S; Mattei C; Di Cesare E; Jannini EA; Festuccia C
Prostate; 2015 Sep; 75(12):1227-46. PubMed ID: 26073897
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-9 inhibits growth and invasion of head and neck cancer cells and is a predictive biomarker of response to plerixafor, an inhibitor of its target CXCR4.
Hersi HM; Raulf N; Gaken J; Folarin N; Tavassoli M
Mol Oncol; 2018 Dec; 12(12):2023-2041. PubMed ID: 29959873
[TBL] [Abstract][Full Text] [Related]
12. Development of functional poly(amido amine) CXCR4 antagonists with the ability to mobilize leukocytes and deliver nucleic acids.
Wang Y; Hazeldine ST; Li J; Oupický D
Adv Healthc Mater; 2015 Apr; 4(5):729-38. PubMed ID: 25491178
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of CXCR4 activity with AMD3100 decreases invasion of human colorectal cancer cells in vitro.
Li JK; Yu L; Shen Y; Zhou LS; Wang YC; Zhang JH
World J Gastroenterol; 2008 Apr; 14(15):2308-13. PubMed ID: 18416455
[TBL] [Abstract][Full Text] [Related]
14. Poly(ethylene glycol)- block-poly(2-aminoethyl methacrylate hydrochloride)-Based Polyplexes as Serum-Tolerant Nanosystems for Enhanced Gene Delivery.
Santo D; Mendonça PV; Lima MS; Cordeiro RA; Cabanas L; Serra A; Coelho JFJ; Faneca H
Mol Pharm; 2019 May; 16(5):2129-2141. PubMed ID: 30986077
[TBL] [Abstract][Full Text] [Related]
15. AMD3100 combined with triptolide inhibit proliferation, invasion and metastasis and induce apoptosis of human U2OS osteosarcoma cells.
Jiang C; Fang X; Zhang H; Wang X; Li M; Jiang W; Tian F; Zhu L; Bian Z
Biomed Pharmacother; 2017 Feb; 86():677-685. PubMed ID: 28038429
[TBL] [Abstract][Full Text] [Related]
16. Cyclam-Modified PEI for Combined VEGF siRNA Silencing and CXCR4 Inhibition To Treat Metastatic Breast Cancer.
Zhou Y; Yu F; Zhang F; Chen G; Wang K; Sun M; Li J; Oupický D
Biomacromolecules; 2018 Feb; 19(2):392-401. PubMed ID: 29350899
[TBL] [Abstract][Full Text] [Related]
17. Reversibly shielded DNA polyplexes based on bioreducible PDMAEMA-SS-PEG-SS-PDMAEMA triblock copolymers mediate markedly enhanced nonviral gene transfection.
Zhu C; Zheng M; Meng F; Mickler FM; Ruthardt N; Zhu X; Zhong Z
Biomacromolecules; 2012 Mar; 13(3):769-78. PubMed ID: 22277017
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effect of CXCR4 antagonist AMD3100 on the tumorigenic cell line of BHP10-3 papillary thyroid cancer cells.
Jung YH; Lee DY; Cha W; Kim BH; Sung MW; Kim KH; Ahn SH
Head Neck; 2016 Oct; 38(10):1479-86. PubMed ID: 27061747
[TBL] [Abstract][Full Text] [Related]
19. Bioreversibly crosslinked polyplexes of PEI and high molecular weight PEG show extended circulation times in vivo.
Neu M; Germershaus O; Behe M; Kissel T
J Control Release; 2007 Dec; 124(1-2):69-80. PubMed ID: 17897749
[TBL] [Abstract][Full Text] [Related]
20. A novel CXCR4 antagonist for hematopoietic stem cell mobilization.
Fricker SP
Expert Opin Investig Drugs; 2008 Nov; 17(11):1749-60. PubMed ID: 18922110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
